Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.9228 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0051 | 0.5902 | 0.5465 |
Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.5902 | 0.6319 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0051 | 0.5902 | 0.5465 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0058 | 0.724 | 1 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0022 | 0.0535 | 0.0739 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0022 | 0.0535 | 0.0679 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0058 | 0.724 | 1 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0035 | 0.2951 | 0.4076 |
Loa Loa (eye worm) | hypothetical protein | 0.0035 | 0.2917 | 0.3017 |
Brugia malayi | Bromodomain containing protein | 0.0037 | 0.3378 | 0.2673 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0051 | 0.5902 | 0.6319 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.3391 | 0.3541 |
Schistosoma mansoni | bromodomain containing protein | 0.0062 | 0.7886 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.4163 | 0.4395 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0035 | 0.2917 | 0.2163 |
Schistosoma mansoni | hypothetical protein | 0.0035 | 0.2917 | 0.3699 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0022 | 0.0535 | 0.0739 |
Schistosoma mansoni | hypothetical protein | 0.002 | 0.0191 | 0.0242 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0035 | 0.2951 | 0.4076 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.3818 | 0.4014 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = -7 % | DNDI: Inhibition of Human African Trypanosomiasis, SBRI 427, in vitro at 2 ug.mL-1 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.